STipe Therapeutics ApS, a 2018 spinout of Aarhus University in Denmark, has raised €20 million in Series A financing to advance a technology for targeting solid tumours by modulating the stimulator of interferon genes (STING) pathway. This pathway is a major driver of innate immunity.
